EKF Diagnostics (LSE:EKF) said trading during the early part of 2026 has progressed in line with management expectations, providing a positive start to the second year of the company’s five-year strategic development programme.
Ahead of its AGM, the group said it has continued simplifying its product portfolio, increasing focus on core commercial opportunities and strengthening its marketing capabilities to support future organic growth initiatives.
The company reported strong operational cash generation and confirmed a cash balance of £15.0 million as of 8 May. EKF also continues to invest internally across the business while maintaining its ongoing share buyback programme.
Demand for the group’s hematology instruments and consumables remained strong during the period. Within life sciences, EKF said β-HB sales exceeded expectations and the contract fermentation pipeline continued to expand, supporting confidence that the company will achieve current market expectations for 2026 revenue and adjusted EBITDA.
The company’s broader outlook is underpinned by a conservative balance sheet with low debt levels and solid cash generation, helping to limit financial risk. However, these strengths are partly offset by uneven revenue trends and profitability that remains significantly below earlier peak performance levels. Technical indicators are mixed, while valuation remains a concern due to a relatively high price-to-earnings ratio and the absence of notable dividend yield support.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings is an AIM-listed global diagnostics business focused on point-of-care testing solutions for haematology and diabetes, alongside life sciences operations producing specialist enzymes and custom products for diagnostic, food and industrial applications. Headquartered in Penarth near Cardiff, the company operates manufacturing facilities in the United States and Germany and distributes products to more than 120 countries worldwide.









